Form D · Other Technology
PharmaCCX, Inc.
Boston, MA · CIK 0001759780
Offering snapshot reported Jul 18, 2023 · SEC filing
- Reported sold
- $5.4M Offering amount: $5.45M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 26, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 18, 2023 | Initial | $5,396,496 | No comparison | 24 | SEC filing |
| Mar 19, 2020 | Initial | $3,000,004 | No comparison | 4 | SEC filing |
| Nov 27, 2018 | Initial | $3,260,298 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-487208
Source: Form D, filed Jul 18, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Julia Bernstein | Director |
| Rob Kniaz | Director |
| Peter Rice | Executive |
| Nathan Sigworth | Director, Executive |
| Armen Solakhyan | Executive |
| Barath Shankar Subramanian | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
867 Boylston Street Pmb 211
Boston, MA, 02116
Boston, MA, 02116